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 The recent development of the Coronavirus Disease 19 (COVID-19) had caused a global 
pandemic with significant impact on healthcare system.  Similar to the acute infection with the 
Middle East Respiratory Syndrome Coronavirus (MERS-CoV), the infection with the SARS-CoV-2, 
causative agent of COVID-19, is associated with asymptomatic infection [1].  Testing for MERS-
CoV and SARS-CoV-2 is currently dependent on molecular testing (rt-PCR).  There were multiple 
generation of molecular tests that were developed over the proceeding few months in an effort 
to improve the sensitivity and specificity. However, there is a global shortage of molecular tests 
for SARS-CoV-2 with expanding scope of testing in many countries to identify cases for the 
isolation and application of quarantine measures. For serologic diagnosis of MERS-CoV and 
SARS-CoV-2 infections, the identifications of antibodies require both acute and convalescent 
serum sampling.  This is particularly important as we witness an increased number of 
asymptomatic or pre-symptomatic COVID-19 infections.  It is understandable that such 
serologic tests are not performed routinely to diagnose respiratory viral infections.  However, it 
is not known if asymptomatic individuals are able to mount an antibody response.   Serologic 
testing enables us to understand the extent of the tip of the iceberg (death rate) as we detect 
more asymptomatic individuals.    
 
Serologic testing enables policy makers to make informed scientific decisions regarding the 
resumption of usual life and lifting social distancing and lockdown of cities especially if we have 
the 50-60% seroprevalence which is taken as a signal of herd immunity.   
Serologic tests will enable the healthcare community to understand the extent of the infection 
as well as be an important tool to identify those who are already immune such as healthcare 
workers.  Identification of immune HCWs would allow those to go back to work.  In addition, 
serology would be particularly important to assess the effectiveness of any vaccines.   
The development of serologic tests requires better understanding of the SARS-CoV-2 structure, 
and the immunologic response to the virus.  The most appealing site for such antibodies is the 
Spike (S) protein of the SARS-CoV-2.  However, there are multiple parts of the S-protein and it is 
not clear which part of this protein offers the best site for antibody development [2] .  It is also 
important to make sure that these antibody tests are unique and do not cross react with the 
widely distributed common cold coronaviruses or MERS-CoV in areas of its endemicity.  One 
study of three patients showed cross-reactivity with the SARS-CoV S and S1 proteins, and to a 
lower extent with MERS-CoV S protein, but not with the MERS-CoV S1 protein [3].  An excellent 
serologic test would be 100% sensitive and 100% specific especially for measuring SARS-CoV-2 S 
and RDB IgA, IgG, and IgM antibodies. 
Having a helpful serology requires that we know that such antibodies are specific, confirm a 
long immunity and know how these antibodies protect against infection to avoid the false sense 
of security in relation to infection.  An additional area of concern is the need to have a 
diagnostic stewardship as these tests will not be helpful in the diagnosis of acute COVID-19 
infection.  An early study of SARS-CoV-2 patients showed the presence of IgM antibodies in 50% 
(8/16) and in 81% (13/16), and that IgG antibodies were detected in 81% (13/16) and 100% 
(16/16) of patients over time [4] and IgM was detected in other studied patients [5].  The 
seroconversion was said to occur in 2 weeks in one study [3].  The S1 IgG and IgA ELISAs had 
lower specificity with variable sensitivity and that IgA ELISA had higher sensitivity [3]. 
In a study of contacts of a patient with mild symptoms, evaluation of IgM and IgG antibodies 
against SARS-CoV-2 was analyzed by immunofluorescence assays (IFA) based on Vero E6 cells.  
In the index patient IgG and IgM were undetectable on day 4 after onset of symptoms, 
however, IgG titers were 80 and 1,280 and those of IgM were 80 and 320 on days 9 and 20, 
respectively [6].  None of the 19 healthcare contacts were positive [6].  In the case of SARS-CoV, 
the detection of antibodies was possible on days 3-42 for IgM and on days 5-47 for IgG [7]. 
There are few studies addressing serology to different SARS-CoV-2 antigens.  One study of three 
patients, antibodies were detected against S1 subunit and RBD, and only two patients had 
detectable antibodies to the N-terminal (S1A) domain [3].  Serologic testing may also facilitate 
the diagnosis of SARS-CoV-2 infection in families.  One study showed a family cluster of COVID-
19 among 5 of 6 members by serology vs. 2 members based on PCR testing [8]. 
Looking back at the lessons we learned from the MERS-CoV serology we could deduce few 
similarities and differences with SARS-CoV-2.  In family contacts of MERS-CoV cases, serologic 
analysis showed that of 280 contacts, 19 (6.7%) had positive recombinant enzyme-linked 
immunosorbent assay (rELISA) S1, 6 (2.1%) had positive recombinant immunofluorescence 
assay (rRIFA) full S, and only 4 (1.4%) had positive plaque-reduction neutralization testing (PRN) 
[8].  However, a follow up samples 2-6 months later showed serologic positivity among 44 
samples of 5 (11.4%), 2 (4.5%), and 1 (2.3%) using rELISA, rRIFA, and PRN, respectively [9]. This 
study showed the following: subclinical transmission in the families, a minority of contacts had 
positive serology and a fraction had persistent antibodies months after infection.  Currently, we 
do not have studies of SARS-CoV-2 serology extending overtime to document the persistence of 
these antibodies. 
An area where serology would be beneficial is surveillance and this is an awaited step to 
understand the epidemiology of SARS-CoV-2 infection.  However, for MERS-CoV there was a 
nation-wide serosurviellance study in Saudi Arabia.  That study examined the serologic 
response in 10,009 individuals and showed that anti-MERS-CoV antibodies were confirmed in 
15 (0·15%; 95% CI 0·09–0·24) [10].  There is a large variation in the diagnostic capabilities of 
different serologic assays in different laboratories and it was recommended that laboratories 
use a testing algorithm including >2 tests to ensure correct diagnosis of MERS-CoV [11].  In 
addition, MERS-CoV S1 protein-based ELISA was used for surveillance studies and was found to 
have a low sensitivity in detecting infection in PCR-confirmed patients with mild clinical 
symptoms [12]. Although, patients with mild MERS-CoV infection as detected by PCR tests had 
seroconversion, not all of them had detectable levels of virus-neutralizing antibodies [12]. This 
may indicates that the presence of anti-MERS-CoV antibodies might not indicate immunity. 
Thus, currently the evidence for the use of serologic testing of SARS-CoV-2 is not optimal.  
These tests are subject to variability in sensitivity and specificity, differences in the timing of the 
appearance of antibodies, and whether these antibodies confirm protection is not known.  This 
is particularly important when making decisions about HCWs who might be at risk of 
contracting SARS-CoV-2. 
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